Isabel Aznarez
Founder bei STOKE THERAPEUTICS, INC.
Profil
Isabel Aznarez is the founder of Stoke Therapeutics, Inc. which was founded in 2014.
She holds the title of Senior Vice President-Discovery Research at Stoke Therapeutics, Inc. Dr. Aznarez's current job is as a Director at Oligonucleotide Therapeutics Society, Inc. since 2019.
Dr. Aznarez obtained a doctorate degree from the University of Toronto in 2006 and also has an undergraduate degree from Universidad De La Republica Uruguay.
Aktive Positionen von Isabel Aznarez
Unternehmen | Position | Beginn |
---|---|---|
STOKE THERAPEUTICS, INC. | Founder | 01.06.2014 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Director/Board Member | 01.01.2019 |
Ausbildung von Isabel Aznarez
University of Toronto | Doctorate Degree |
Universidad De La Republica Uruguay | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
STOKE THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |